• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂蛋白脂肪酶在形成血管生成素样蛋白 4 低聚物的 THP-1 巨噬细胞表面失活。

Inactivation of lipoprotein lipase occurs on the surface of THP-1 macrophages where oligomers of angiopoietin-like protein 4 are formed.

机构信息

Department of Medical Biosciences, Physiological Chemistry Umeå University, SE-901 87 Umeå, Sweden.

出版信息

Biochem Biophys Res Commun. 2012 Aug 24;425(2):138-43. doi: 10.1016/j.bbrc.2012.07.048. Epub 2012 Jul 20.

DOI:10.1016/j.bbrc.2012.07.048
PMID:22820186
Abstract

Lipoprotein lipase (LPL) hydrolyzes triglycerides in plasma lipoproteins causing release of fatty acids for metabolic purposes in muscles and adipose tissue. LPL in macrophages in the artery wall may, however, promote foam cell formation and atherosclerosis. Angiopoietin-like protein (ANGPTL) 4 inactivates LPL and ANGPTL4 expression is controlled by peroxisome proliferator-activated receptors (PPAR). The mechanisms for inactivation of LPL by ANGPTL4 was studied in THP-1 macrophages where active LPL is associated with cell surfaces in a heparin-releasable form, while LPL in the culture medium is mostly inactive. The PPARδ agonist GW501516 had no effect on LPL mRNA, but increased ANGPTL4 mRNA and caused a marked reduction of the heparin-releasable LPL activity concomitantly with accumulation of inactive, monomeric LPL in the medium. Intracellular ANGPTL4 was monomeric, while dimers and tetramers of ANGPTL4 were present in the heparin-releasable fraction and medium. GW501516 caused an increase in the amount of ANGPTL4 oligomers on the cell surface that paralleled the decrease in LPL activity. Actinomycin D blocked the effects of GW501516 on ANGPTL4 oligomer formation and prevented the inactivation of LPL. Antibodies against ANGPTL4 interfered with the inactivation of LPL. We conclude that inactivation of LPL in THP-1 macrophages primarily occurs on the cell surface where oligomers of ANGPTL4 are formed.

摘要

脂蛋白脂肪酶(LPL)水解血浆脂蛋白中的甘油三酯,为肌肉和脂肪组织的代谢目的释放脂肪酸。然而,动脉壁中的巨噬细胞中的脂蛋白脂肪酶可能促进泡沫细胞的形成和动脉粥样硬化。血管生成素样蛋白(ANGPTL)4 使脂蛋白脂肪酶失活,ANGPTL4 的表达受过氧化物酶体增殖物激活受体(PPAR)控制。在 THP-1 巨噬细胞中研究了 ANGPTL4 使 LPL 失活的机制,其中活性 LPL 以肝素可释放的形式与细胞表面相关,而培养基中的 LPL 主要是无活性的。PPARδ激动剂 GW501516 对 LPL mRNA 没有影响,但增加了 ANGPTL4 mRNA,并导致肝素可释放的 LPL 活性显著降低,同时在培养基中积累了无活性的单体 LPL。细胞内的 ANGPTL4 是单体,而二聚体和四聚体的 ANGPTL4 存在于肝素可释放部分和培养基中。GW501516 增加了细胞表面 ANGPTL4 寡聚体的数量,与 LPL 活性的降低相平行。放线菌酮 D 阻断了 GW501516 对 ANGPTL4 寡聚体形成的影响,并阻止了 LPL 的失活。针对 ANGPTL4 的抗体干扰了 LPL 的失活。我们的结论是,THP-1 巨噬细胞中 LPL 的失活主要发生在形成 ANGPTL4 寡聚体的细胞表面。

相似文献

1
Inactivation of lipoprotein lipase occurs on the surface of THP-1 macrophages where oligomers of angiopoietin-like protein 4 are formed.脂蛋白脂肪酶在形成血管生成素样蛋白 4 低聚物的 THP-1 巨噬细胞表面失活。
Biochem Biophys Res Commun. 2012 Aug 24;425(2):138-43. doi: 10.1016/j.bbrc.2012.07.048. Epub 2012 Jul 20.
2
Inactivation of lipoprotein lipase in 3T3-L1 adipocytes by angiopoietin-like protein 4 requires that both proteins have reached the cell surface.血管生成素样蛋白 4 使 3T3-L1 脂肪细胞中的脂蛋白脂肪酶失活需要这两种蛋白都到达细胞表面。
Biochem Biophys Res Commun. 2013 Nov 29;441(4):941-6. doi: 10.1016/j.bbrc.2013.11.013. Epub 2013 Nov 9.
3
Angiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes.血管生成素样蛋白 4 介导线粒体甘油三酯酶依赖的脂肪酸摄取,但不介导线粒体脂肪酸β氧化,是过氧化物酶体增殖物激活受体 δ 发挥作用的关键因素。
PLoS One. 2012;7(10):e46212. doi: 10.1371/journal.pone.0046212. Epub 2012 Oct 4.
4
Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue.血管生成素样蛋白4将脂蛋白脂肪酶转化为无活性单体,并调节脂肪组织中的脂肪酶活性。
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17450-5. doi: 10.1073/pnas.0604026103. Epub 2006 Nov 6.
5
MicroRNA-134 actives lipoprotein lipase-mediated lipid accumulation and inflammatory response by targeting angiopoietin-like 4 in THP-1 macrophages.微小RNA-134通过靶向THP-1巨噬细胞中的血管生成素样蛋白4激活脂蛋白脂肪酶介导的脂质积累和炎症反应。
Biochem Biophys Res Commun. 2016 Apr 8;472(3):410-7. doi: 10.1016/j.bbrc.2015.10.158. Epub 2015 Nov 4.
6
Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation.血管生成素样蛋白 4 对脂蛋白脂肪酶的抑制:可逆复合物形成的证据。
J Biol Chem. 2013 Oct 4;288(40):28524-34. doi: 10.1074/jbc.M113.497602. Epub 2013 Aug 19.
7
Regulation of lipoprotein lipase by Angptl4.Angptl4 对脂蛋白脂肪酶的调节。
Trends Endocrinol Metab. 2014 Mar;25(3):146-55. doi: 10.1016/j.tem.2013.12.005. Epub 2014 Jan 4.
8
Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake.血管生成素样蛋白4通过抑制脂蛋白脂肪酶和肝脂酶依赖的肝脏胆固醇摄取来上调肝脏中的胆固醇合成。
Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2420-7. doi: 10.1161/ATVBAHA.107.151894. Epub 2007 Aug 30.
9
Angiopoietin-like 4 Modifies the Interactions between Lipoprotein Lipase and Its Endothelial Cell Transporter GPIHBP1.血管生成素样蛋白4改变脂蛋白脂肪酶与其内皮细胞转运体GPIHBP1之间的相互作用。
J Biol Chem. 2015 May 8;290(19):11865-77. doi: 10.1074/jbc.M114.623769. Epub 2015 Mar 25.
10
Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development.血管生成素样蛋白 4 过表达可预防动脉粥样硬化发展。
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1529-37. doi: 10.1161/ATVBAHA.113.301698. Epub 2013 May 2.

引用本文的文献

1
Combined action of albumin and heparin regulates lipoprotein lipase oligomerization, stability, and ligand interactions.白蛋白和肝素的联合作用调节脂蛋白脂肪酶的寡聚化、稳定性和配体相互作用。
PLoS One. 2023 Apr 12;18(4):e0283358. doi: 10.1371/journal.pone.0283358. eCollection 2023.
2
Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma.脂蛋白大小是影响外源性脂蛋白脂肪酶在人血浆中水解速率的主要决定因素。
J Lipid Res. 2022 Jan;63(1):100144. doi: 10.1016/j.jlr.2021.100144. Epub 2021 Oct 26.
3
The Importance of Lipoprotein Lipase Regulation in Atherosclerosis.
脂蛋白脂肪酶调节在动脉粥样硬化中的重要性。
Biomedicines. 2021 Jul 6;9(7):782. doi: 10.3390/biomedicines9070782.
4
GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity.糖基磷脂酰肌醇锚定高密度脂蛋白结合蛋白1(GPIHBP1)和血管生成素样蛋白4(ANGPTL4)利用蛋白质无序化来协调血浆甘油三酯代谢中的有序性并调节脂蛋白脂肪酶(LPL)活性的区室化。
Front Cell Dev Biol. 2021 Jul 15;9:702508. doi: 10.3389/fcell.2021.702508. eCollection 2021.
5
Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the "Prime Time" of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?ANGPTL4 与功能缺失变异在脂代谢和冠心病中的作用研究进展:针对冠心病的 ANGPTL4 靶向治疗“黄金时代”是否即将到来?
Cardiovasc Drugs Ther. 2021 Jun;35(3):467-477. doi: 10.1007/s10557-020-07001-0.
6
Simple and rapid real-time monitoring of LPL activity .简单快速地实时监测脂蛋白脂肪酶活性。
MethodsX. 2020 Mar 17;7:100865. doi: 10.1016/j.mex.2020.100865. eCollection 2020.
7
Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes.血管生成素样蛋白 3 对甘油三酯调节、血糖稳态和糖尿病的影响。
Dis Markers. 2019 Mar 3;2019:6578327. doi: 10.1155/2019/6578327. eCollection 2019.
8
On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity.关于血管生成素样蛋白 8 控制脂蛋白脂肪酶活性的机制。
J Lipid Res. 2019 Apr;60(4):783-793. doi: 10.1194/jlr.M088807. Epub 2019 Jan 27.
9
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy.富含甘油三酯的脂蛋白与抗动脉粥样硬化治疗的新靶点
Korean Circ J. 2018 Dec;48(12):1097-1119. doi: 10.4070/kcj.2018.0343.
10
Hypertriglyceridaemia and risk of coronary artery disease.高甘油三酯血症与冠心病风险。
Nat Rev Cardiol. 2017 Jul;14(7):401-411. doi: 10.1038/nrcardio.2017.31. Epub 2017 Mar 16.